Trial Profile
An Exploratory Single-center, Open-label , Clinical Study of Apatinib in Patients With Local Progressive/Metastatic Refractory Thyroid Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Sep 2023
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Adenocarcinoma; Thyroid cancer
- Focus Therapeutic Use
- 29 Jun 2017 New trial record